Eotaxin-3 (CCL26), like eotaxin (CCL11) and eotaxin-2 (CCL24), has long been considered a specific agonist for CC chemokine receptor 3 (CCR3), attracting and activating eosinophils, basophils, and Th2 type T lymphocytes. Although not characterized extensively yet, its expression profile coincides with a potential role in allergic inflammation. We recently reported that eotaxin-3 is an antagonist for CCR2 (Ogilvie, P., Paoletti, S., ClarkLewis, I., and Uguccioni, M. (2003) Blood 102, 789 -784). In the present report, we provide evidence that eotaxin-3 acts as a natural antagonist on CCR1 and -5 as well. Eotaxin-3 bound to cells transfected with either CCR1 or -5 as well as to monocytes expressing both receptors. Further, it inhibited chemotaxis, the release of free intracellular calcium, and actin polymerization when cells were stimulated with known agonists of CCR1 and -5. An analysis of its three-dimensional structure indicated the presence of two distinct epitopes that may be involved in specific binding to CCR1, -2, -3, and -5. Taken together, our data thus indicate eotaxin-3 to be the first human chemokine that features broadband antagonistic activities, suggesting that it may have a modulatory rather than an inflammatory function. Further, eotaxin-3 may play an unrecognized role in the polarization of cellular recruitment by attracting Th2 lymphocytes as well as eosinophils and basophils via CCR3, while concomitantly blocking the recruitment of Th1 lymphocytes and monocytes via CCR1, -2, and -5.
The eotaxins (eotaxin (CCL11), 1 eotaxin-2 (CCL24), and eotaxin-3 (CCL26)) have been reported as selective agonists for CC chemokine receptor 3 (CCR3), hence attracting CCR3-bearing cells like eosinophils, basophils and Th2 lymphocytes, which are typically found in allergic inflammation (1) (2) (3) (4) (5) . In pathological conditions and upon the production of Th2 cytokines, eotaxins and other CCR3 recruiting chemokines were found to be expressed in several tissues (6 -8) . Eotaxin-3 shares 36 and 32% of sequence homology to eotaxin and eotaxin-2, respectively, but is a less potent agonist of CCR3 (9) . It was reported to be expressed in vascular endothelial cells after interleukin-4 and -13 stimulation (10) and in bronchial tissue upon allergen challenge (11) . Recently, the mRNA expression of eotaxin-3 was detected in dermal fibroblasts, implying a role in the pathogenesis of allergic and autoimmune diseases (12) .
Antagonism of natural chemokines, as opposed to their known agonistic properties, has been described only recently. Such dual-activity chemokines would attract or activate a population of cells bearing one receptor, while at the same time preventing the recruitment and/or cellular activation of a different cellular population via another receptor. So far, six reports describe seven natural chemokine antagonists (13) (14) (15) (16) (17) (18) . The natural form of dendritic cell-derived chemokine 1 (CCL18) inhibits CCR3 (17) , although less strongly than an N-terminal alanine to methionine mutant (14) . A thorough pharmacological characterization of CCR5 characterized MCP-3 (CCL7), a promiscuous agonist for CCR1, -2, and -3, as a highly potent CCR5 antagonist (13) . Another extensive study showed the interferon-inducible T cell ␣ chemoattractant (CXCL11), an agonist of CXCR3, to be a highly selective and potent antagonist for CCR3 (15) , whereas the monocyte/macrophage-activating IFN-␥-inducible protein (CXCL9) and the IFN-␥-inducible 10-kDa protein (CXCL10), the other two agonists of CXCR3, were less efficient inhibitors. More recently, eotaxin (CCL11) and eotaxin-3 (CCL26) have been reported to have antagonistic effects on CCR2 (16, 18) . Generally, understanding the natural antagonism of chemokines might help to clarify how one cell population gets recruited and activated, while at the same time another one is inhibited. Although in vivo experiments with natural antagonists have yet to be performed, synthetic and viral chemokine antagonists have proven to be effective already; N-terminally truncated MCP-1 (9 -76) prevented the onset of disease and reduced symptoms and cellular infiltration in the MRL-lpr mouse model (19) , and truncated secondary lymphoid tissue chemokine prevented the development of graft versus host disease in mice (20) . vMIP-II inhibited leukocyte infiltration, attenuated glomerulonephritis in Wistar-Kyioto rats (21) , and inhibited virus-induced inflammation in mice (22) .
In the present study, we show eotaxin-3 to be a natural antagonist for CCR1 and -5. Taken together with our previous report (18) about the antagonistic activity of eotaxin-3 on CCR2, eotaxin-3 would be the first broadband human chemokine antagonist, suggesting a modulatory rather than inflammatory role for this chemokine.
EXPERIMENTAL PROCEDURES
Chemokine Synthesis-All chemokines were chemically synthesized using t-butoxycarbonyl solid-phase chemistry (23) .
Cells-Peripheral blood mononuclear cells were isolated from buffy coats of donor blood (Central Laboratory of the Swiss Red Cross, Basel, Switzerland) by Fycoll-Paque® density centrifugation. CD14 ϩ monocytes were isolated by a positive immunoselection procedure (CD14 Micro Beads, Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions, cultured overnight in complete RPMI 1640 with 10% fetal calf serum to up-regulate CCR5, and confirmed to express CCR1 and -5 by flow cytometry. Stable transfection of human CCR1 and -5 into murine pre-B 300.19 cells was performed as described previously (16) .
Chemotaxis Assays-Chemotaxis was assayed in 48-well Boyden microchambers (Neuro Probe Inc., Cabin John, MD) by using polyvinylpryrrolidone-free polycarbonate membranes with 5-m pores (Nucleopore). Briefly, attracting chemokines diluted in chemotaxis buffer (RPMI 1640, 20 mM Hepes, pH 7.4, containing 0.05% pasteurized plasma protein from the Swiss Red Cross Laboratory, Bern, Switzerland) were placed in the lower wells. In all inhibition experiments, eotaxin-3 was placed in the upper and lower wells. 5 ϫ 10 4 monocytes/ well or pre-B murine 300.19 cells/well singly transfected with CCR1 or -5 were resuspended in chemotaxis buffer. After 60 min of incubation for monocytes and 120 min of incubation for transfected cells, the membrane was removed, washed on the upper side with phosphatebuffered saline, fixed, and stained. Migrated cells were counted at 1000ϫ magnification in five fields/well. All experiments were performed in triplicates. Data of dose-response experiments were fit to a sigmoidal function with variable slope using PRISM (GraphPad Software, San Diego, CA).
Chemokine Receptor Expression and Internalization-CCR1, -2, and -5 expression in monocytes cultured overnight was analyzed by flow cytometry (FACScan™, BD Biosciences, San Jose, CA). Cells were incubated for 30 min in FACS buffer (2% fetal calf serum, 0.1% sodium azide in phosphate-buffered saline) with anti-CCR1 (2D4, LeukoSite, Cambridge, MA), anti-CCR2b (MAB150, R&D Systems, UK), or anti-CCR5 (MAB181, R&D Systems).
Calcium Transients-CCR1-or CCR5-transfected cells and monocytes were loaded in RPMI 1640 containing 20 mM Hepes and 5% fetal calf serum, with 0.16 nmol of fura-2/AM/million cells for 20 min. Intracellular Ca 2ϩ mobilization was measured after single or sequential stimulation with chemokines by recording [Ca 2ϩ ] i -related fluorescence changes (24) . Receptor internalization was assessed accordingly after a 45-min incubation at room temperature with 1 M of either RANTES or eotaxin-3, respectively.
Actin Polymerization-F-actin formation was determined with fluorescein isothiocyanate-coupled phalloidin (Sigma-Aldrich Chemicals) in chemokine-stimulated CCR1-or CCR5-transfected cells and freshly isolated human monocytes. The reaction was stopped after 10 s, and cells were fixed with cold paraformaldehyde (4%) in phosphate-buffered saline for 30 min on ice. For experiments with consecutive exposure to two different chemokines, cells were pretreated with one chemokine for 3 min, exposed to the second chemokine, and fixed after 10 s as described above. After paraformaldehyde fixation, cells were permeabilized with 0.1% Triton X-100, stained with fluorescein isothiocyanateconjugated phalloidin (6 g/ml), and analyzed by FACS. All experiments were performed in duplicate. Relative F-actin formation was calculated as the percentage of agonist-induced and basal phalloidin staining (100%).
Receptor Binding-Competition binding assays were performed with CCR1-or CCR5-transfected cells and monocytes using 2 ϫ 10 6 cells in 120 l of RPMI 1640 containing 20 mM Hepes and 1% bovine serum albumin, pH 7.1. Cells were incubated on ice for 90 min with 0.15 nM 125 I-MIP-1␣ (Amersham Biosciences) and competing chemokines as indicated. Non-bound radioactivity was separated by centrifugation through 6% bovine serum albumin in phosphate-buffered saline, and cell-bound radioactivity was determined by ␥-counting. The difference between total (radioligand only) and nonspecific binding (1000 nM unlabeled MIP-1␣ added) was taken as 100%. Data were analyzed with PRISM, using nonlinear regression in one-or two-site binding models.
Protein Display and Analysis-Coordinates for eotaxin-3 (PDB code 1G2S), vMIP-II (PDB code 1VMP), MCP-2 (PDB code 1ESR), and MCP-3 (PDB code 1BO0) were obtained from the Protein Data Bank. Superposition fits and graphical analysis were performed in Swiss Pdb Viewer (25) . The electrostatic potentials are shown according to Poisson-Boltzmann where blue designates basic (7) residues, and red designates acidic (Ϫ7) residues. Pairwise sequence alignments were performed using the standard settings of ClustalW, and multiple sequence alignments were performed using the global sequences without end-gap penalty settings of LALIGN at ch.EMBnet.org. As shown in Fig. 4 , the asterisk designates identity, the colon designates high similarity (log score of 0 or greater in the default blosum matrix), and the period designates low similarity (log score of Ϫ1 or greater in the default blosum matrix) between amino acids. The term "conserved" is used throughout for log scores of Ϫ1 or greater between amino acids. ϩ /CCR5 ϩ monocytes that had been cultured overnight. Cells were sequentially exposed to increasing concentrations of eotaxin-3 and to RANTES at concentrations sufficient to induce cellular responses. Eotaxin-3 inhibited responses to RANTES in a dose-dependent manner in all cell types. In transfected cells (Fig. 1, A and B) , the response induced by 10 nM RANTES was partially inhibited by 300 nM eotaxin-3, whereas at 1 M inhibition was complete. Eotaxin-3 was a more potent antagonist for CCR5, blocking the response almost completely at 300 nM. In monocytes stimulated with 30 nM RANTES (Fig. 1C) , we observed substantial inhibition only after pretreatment with 1 M eotaxin-3 but not with lower concentrations. The monocyte preparations used in these (and all subsequent) experiments were CCR1 ϩ and CCR5 ϩ , and the simultaneous stimulation of the two receptors seems the likely explanation for the slightly reduced inhibitory potency of eotaxin-3 on these cells.
RESULTS AND DISCUSSION

Eotaxin-3 (CCL26) Inhibits Functional Responses
To further characterize the antagonistic activity of eotaxin-3, we performed chemotaxis assays. In experiments with transfected cells, increasing concentrations of MIP-1␣ (a high potency agonist for CCR1 and -5) were added to the lower wells of the chemotaxis chamber. In the presence of 1 M eotaxin-3 in the upper and lower wells, we observed almost complete inhibition of cell migration with CCR1-transfected ( Fig. 1D ) as well as CCR5-transfected cells (Fig. 1E) . On transfected cells, eotaxin-3 alone had no chemotactic effects if applied to the upper, lower, or both wells. However and as we have reported previously (18) , eotaxin-3 actively repulses monocytes (but not receptor-transfected 300.19 cells) in vitro if an inverse gradient of eotaxin-3 is present. To avoid interference of this effect with inhibition of chemotaxis in monocytes (Fig. 1F) , eotaxin-3 at 1 M was added to the lower and upper wells of the chemotaxis chambers again. As with transfected cells, eotaxin-3 markedly reduced monocyte migration toward MIP-1␣. The inhibitory effect was slightly less pronounced than in transfected cells. However, monocytes used were CCR1 ϩ and CCR5 ϩ , which might readily account for the slightly higher migration observed. To confirm that eotaxin-3 itself does not induce any cell movement, eotaxin-3 was added alone to the upper and lower wells at 1 M where it did not induce any cell migration above background (cell migration toward buffer).
To estimate the dose of eotaxin-3 necessary to inhibit agonist-induced migration, an optimal concentration of MIP-1␣ was added to the lower wells of the chemotaxis chambers, and chemotaxis in the presence of increasing concentrations of eotaxin-3 assayed. In CCR1-and CCR5-transfected cells (Fig.  1, G and H) , eotaxin-3 at 1 M abolished cell migration in response to 10 nM MIP-1␣ almost completely. Eotaxin-3 inhibited CCR5 with a slightly higher potency than CCR1. Similar experiments with an optimal dose of 10 nM MIP-1␣ were performed using monocytes (Fig. 1I) . As expected, eotaxin-3 reduced monocyte migration in a dose-dependent manner with a potency roughly intermediate between those observed for CCR1-and CCR5-transfected cells, probably again because of the cumulative effect of simultaneous stimulation of both re-ceptors. The IC 50 values calculated from these experiments are in the high nanomolar range with 622 and 254 nM for CCR1-and CCR5-transfected cells, and 175 nM for monocytes, respectively (see Table I , last row for a summary). The maximal inhibitions achieved with 1 M eotaxin-3 were 88% (CCR1), 86% (CCR5), and 73% (monocytes).
When cells encounter a chemokine gradient, they adopt a highly polarized morphology with a leading edge enriched in F-actin, allowing them to move efficiently through the gradient. To investigate whether eotaxin-3 can inhibit RANTESinduced actin polymerization in cells transfected with CCR1 or -5 and in monocytes, cells were stimulated with 10 nM RANTES (set to 100% for all experiments) or sequentially exposed to 1 M eotaxin-3 and to 10 nM RANTES. For both CCR1-and CCR5-transfected cells, we observed inhibition of greater than 50% in the formation of F-actin after pretreatment with 1 M eotaxin-3 (Fig. 1J) . Of note, exposure to 1 M eotaxin-3 alone did not induce any F-actin formation (not shown). Similarly, F-actin formation induced by 10 nM RANTES is inhibited by more than 50% in monocytes after pre-exposure to 1 M eotaxin-3 (Fig. 1K, last bar) . However, because of its repulsive activity, 1 M eotaxin-3 by itself induces a strong response (Fig.  1K, fourth bar and Ref. 18) , which drops to background levels within 3 min (Fig. 1K, fifth bar) . To verify that the inhibition seen in monocytes is caused by receptor antagonism on CCR1 and -5 but not caused by depletion of the globular actin pool or heterologous receptor desensitization, we stimulated CCR2 with 10 nM of its selective agonist MCP-1 (Fig. 1K, first bar) , which induces F-actin polymerization comparable with 10 nM RANTES and 1 M eotaxin-3. Even though 10 nM MCP-1 stimulates monocytes in a more persistent way than 1 M eotaxin-3 with measurable polymerization even after 3 min (Fig. 1K,  second bar) , cells remained fully responsive to a subsequent stimulation of CCR1 and -5 with 10 nM RANTES (Fig. 1K, third  bar) . Taken together, it seems likely that the inhibition of CCR1 and -5 by eotaxin-3 is in fact caused by direct receptor antagonism.
Eotaxin-3 Binds to CCR1 and -5-One of the main features of natural antagonists is their binding to the receptors that they are inhibiting while failing to induce cellular responses. To characterize the binding of eotaxin-3 on CCR1 and -5 in transfected cells as well as in monocytes, we performed competition binding assays. Eotaxin-3 readily inhibited the binding of 125 I-MIP-1␣ on CCR1-or CCR5-transfected cells and monocytes. In CCR1-transfected cells ( Fig. 2A) 
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spectively. In CCR5-transfected cells, (Fig. 2B) , eotaxin-3 bound with 3-or 28-fold lower IC 50 values than the two agonists having IC 50 values of 25 nM for MIP-1␣, 2.3 nM for RAN-TES, and 64 nM for eotaxin-3, respectively. In monocytes (Fig.  2C) , the binding data for RANTES were best fit to a two-site model, resulting in IC 50 values of 15 and 2140 nM, whereas the data for both MIP-1␣ and eotaxin-3 fit best to a one-site model, with apparent IC 50 values of 37 and 383 nM, respectively. Thus, eotaxin-3 displayed a 26-fold lower (high IC 50 value site of RANTES), 10-fold lower (MIP-1␣), and 6-fold higher (low IC 50 value site of RANTES) binding than the two agonists tested (see Table I , first three rows for a summary).
Eotaxin-3 Does Not Alter the Functional Response of Other Chemokine
Receptors-To assess the specificity of eotaxin-3 as a natural antagonist, an additional nine murine pre-B cell lines, singly transfected with different human inflammatory or homing chemokine receptors, were tested for the antagonistic activity of eotaxin-3. Cells were left untreated or exposed to 1 M eotaxin-3 and were sequentially stimulated with receptorspecific chemokines. As shown in Fig. 3 , eotaxin-3 had no effect on any of the nine receptors, suggesting that the antagonistic activity of eotaxin-3 is specific for CCR1, -5, and -2 (18).
Eotaxin-3 Is a Specific Natural Antagonist of CCR1, -2, and -5-Taken
together, our data show that eotaxin-3 acts as a receptor antagonist on CCR1 and -5. Its antagonistic activity is confined to CCR1, -2 (18), and -5, as it did not display any effect on nine other chemokine receptors tested. Eotaxin-3 was able to reduce all functional responses of the monocytes and receptor-transfected 300.19 cells such as chemotaxis, [Ca 2ϩ ] i release, and actin polymerization to minimal levels, and did not induce any receptor internalization (data not shown). As summarized in Table I, Fig. 2 ). The pIC 50 (ϪlogM) values were obtained from functional dose-response curves using the chemotaxis assay (See Fig. 1, G-I 
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somewhat different picture however. At 1 M, eotaxin-3 completely inhibited chemotaxis and [Ca 2ϩ ] i changes in CCR1-transfected cells despite the binding IC 50 value of 1770 nM for eotaxin-3. Receptor occupancy at 1 M would thus be rather low to account for complete inhibition, suggesting another currently unknown mechanism. Of note, similar results have been found independently (16, 26) by the two groups that reported on the antagonism of eotaxin on CCR2. An alternative explanation would be inhibition by chemokine aggregation. Many chemokines form homodimers, and MIP-1␣ and -1␤ are known to form native heterodimers (27) . It is feasible that in a heterocomplex composed of MIP-1␣ and eotaxin-3, eotaxin-3 might inhibit MIP-1␣ binding to (and activation of) CCR1 by direct physical contact. To test this hypothesis, we have performed immunoprecipitation experiments in conditions similar to the ones reported (27) but have not found any evidence in favor of such a heterocomplex (results not shown). Hence, we exclude that eotaxin-3 inhibits the target receptors of MIP-1␣ by chemokine aggregation.
To induce measurable inhibition, concentrations greater than 100 nM were required, with full inhibition observed at 1 M eotaxin-3, raising the question of whether such concentrations can be achieved in a physiological setting. Lacking any information about in vivo concentrations of chemokines in general and of eotaxin-3 in particular, the inhibitory potential might best be compared with its agonistic potency in vitro. Previous (9) as well as our own chemotaxis experiments (data not shown) demonstrate that eotaxin-3 elicits migration only at concentrations reaching or exceeding 300 nM. At such concentrations, eotaxin-3 exerts its inhibitory action on all three target receptors in vitro, indicating that eotaxin-3 might be produced in amounts sufficient for physiological inhibition as well. However, such speculations will need to be confirmed with in vivo experiments.
Sequence and Structural Analysis of Eotaxin-3 Binding to CCR1, -2, -3, and -5-Apart from CCR1 and -5, eotaxin-3 was reported previously to interact with CCR3 (9, 10) and CCR2 (18) . Currently, there are four other chemokines known to feature a similarly broad specificity. MCP-2 (CCL8) and HCC-4 are agonists for all four receptors, whereas MCP-3 (CCL7) is an agonist for CCR1-CCR3 (Refs. 28 and 29 and references therein) and an antagonist for CCR5 (13) . vMIP-II, apart from being an agonist for CCR3, is an antagonist with an even broader range, blocking CCR4, CCR8, CXCR3, and CXCR4 as well (21, 30 -33) . Despite the functional similarity among these five chemokines, their sequence identities are rather modest (25-36%) , with the exception of the much more closely related MCP-2 and -3 (58%), as determined by pairwise alignments (Fig. 4A) . However, a graphical inspection of surface topologies and electrostatic distributions of the four chemokines with solved structures (eotaxin-3 (34), vMIP-II (35), MCP-2 (36), and MCP-3 (37)) reveals similarities as well, which might be the structural base for the promiscuous binding of these five chemokines.
Fig . 4B shows the four chemokines with the N-loop, the ␤2-␤3-loop (40s-loop), and the third ␤-sheet facing the viewer. Together, these domains most likely compose a general chemokine interface that interacts with the N termini of the receptors, representing the major binding interaction between chemokines and receptors, as evidenced by nuclear magnetic resonance (NMR) experiments of interleukin-8 (CXCL8), fractalkine (CX3CL1), eotaxin (CCL11), eotaxin-2 (CCL24), and IFN-␥-inducible 10-kDa protein (CXCL10) in complex with Nterminal peptides from their respective receptors (38 -42) . The mode of receptor interaction of these diverse chemokines is very much alike, and hence we assumed that the chemokines binding CCR1, -2, -3, and -5 would employ a similar mechanism. As to be expected because of their high sequence identity (58%), the binding interfaces of MCP-2 and -3 appear very similar, whereas vMIP-II is rather different from other inflammatory CC-chemokines, as noted before (43, 44) . More surprising is the high similarity between eotaxin-3 and vMIP-II despite their modest sequence identity (36%). In both chemokines, a comparably wide vertical groove is lined by highly basic residues (Fig. 4B ). This groove, corresponding to the interface accommodating the N terminus of CCR3 in eotaxin (41) and eotaxin-2 (40) , is shaped very differently in MCP-2 and -3.
Despite the modest similarities in the overall primary sequence, the structural and functional similarities between the five chemokines binding to all four receptors can be used to make specific predictions about which amino acids might mediate the broad binding specificity of eotaxin-3. Fig. 4C shows an alignment of the above five chemokines that bind to all of the four receptors, with identical (asterisk) and conserved (colon or period) residues indicated directly below (see "Experimental Procedures" for a detailed definition of conserved). Additionally, the result of an alignment of all chemokines that bind to one, two, or three of all four receptors is shown (CCR1, -2, -3, and -5; the actual chemokine sequences have been omitted for brevity). Those 14 positions that are conserved among the chemokines that bind to all four receptors but not conserved among all chemokines that bind to one, two, or three of all four receptors have been highlighted. The pattern of conservation of the colored residues thus correlates with the functional pattern of interest (binding to all four CCR1, -2, -3, and -5) of those five chemokines (eotaxin-3, vMIP-II, MCP-2, MCP-3, and HCC-4). Note that the respective residues have been colored exclusively according to their three-dimensional positions (see below for a detailed explanation).
The spatial location of these 14 positions is shown in Fig. 4D  in a ribbon representation (top row) , using the sequence and solved structure of eotaxin-3 as an example, and with colors corresponding to Fig. 4C . Interestingly, 13 of 14 residues form two distinct epitopes on the surface of eotaxin-3 and are colored yellow or green to illustrate this spatial separation (Fig. 4D,  surface representation in the bottom row) . The yellow epitope is composed of seven residues found in the N terminus and the first ␤-sheet, as well as amino acids proximal to, within, and distal to the 40s-loop. The green epitope is formed by six residues that are located in the N-loop as well as proximal to and within the C-terminal ␣-helix. Of note, all residues are on the solvent-accessible surface of eotaxin-3, the only exception being Thr-51 (gray). Because of their easy accessibility and their receptor-specific patterns of conservation, these residues are likely to mediate the promiscuous recognition of CCR1, -2, -3, and -5 by eotaxin-3. Detailed structure-function studies would be necessary to confirm our speculations that these residues are involved in receptor binding of eotaxin-3. However, it should be noted that for several other chemokines analogous domains and/or residues have been implicated in receptor binding using a variety of methods such as structure-function studies (Refs. 45 and 46 and references therein), NMR structure determinations (38 -42) , structure and sequence analysis (43, 44) , and dynamic modeling (47) .
It is tempting to speculate about the potential physiological consequences that antagonism exerted by eotaxin-3 may bear on cellular recruitment in inflammation. By blocking CCR1, -2, and -5, eotaxin-3 would counteract the effect of all "classical", inflammatory CC-chemokines on any cell type expressing any of these receptors but lacking CCR3. Specifically, eotaxin-3 could interfere with the triggering phase of an immune response by impeding the recruitment of immature dendritic cells, which are known to respond to inflammatory chemokines by expressing CCR1, -2, and -5 (48 -51). Likewise, eotaxin-3 would inhibit the accumulation of effector cells such as CCR1/2 ϩ monocytes, and CCR1/5 ϩ macrophages (52) . Further, eotaxin-3 might skew the balance between a Th1-and Th2-type response toward the Th2 branch, because expression of CCR3 or -5 by T lymphocytes has been correlated with a Th2 or Th1 phenotype, respectively (2, 4, 53, 54) . Finally, eotaxin-3 is a CCR3 agonist of rather low potency, and it has been suggested previously that, acting as a partial agonist, it might negatively regulate the recruitment of CCR3 ϩ cells such as eosinophils into tissues where other more potent CCR3 agonists are present as well (9) . Therefore, the collective evidence presented previously and here might be taken as an indication that eotaxin-3 is not a "typical" inflammatory chemokine but rather a "broad-band" chemokine receptor antagonist, thus serving as a negative regulator of leukocyte migration.
